BOL-303259-X: Phase IIb started

Bausch + Lomb began a single-blind, dose-ranging, international Phase IIb trial in 400 patients to compare once-daily BOL-303259-X vs. Xalatan latanoprost for 28 days. In March, NicOx granted Bausch...